Allen King Email and Phone Number

I lead a team responsible for the Global Market Access and HEOR strategy for Pfizer's Hemophilia A and B Gene Therapies currently in Phase 3 clinical trials

Lead a Global Team of five professionals responsible for securing reimbursement with Government and Private Payers for GE Healthcare’s portfolio of contrast media and radio-pharmaceuticals• Recruited, hired, and lead a field-based US Market Access Team and expanding to Europe in 1Q2015 • Secured significant investment for Phase IV clinical trial to generate utility data required by payers for a cardiovascular imaging agent • Produced clinical and economic dossier for neurological imaging agent and executed 15 private payer submissions to overturn negative medical policy• Secured advocacy support from six Professional and Patient Societies to endorse payer coverage for the GE product portfolio

Responsible for developing the Pricing and Market Access function that leverages the HEOR and evidence generation heritage of the former I3/Innovus● Secured over $1,000,000 in new business in first year of creating the practice from clients ranging from Payer/Brand Directors of major pharmaceutical firms to CEO’s of small biotech companies● Built a Pricing and Market Access function with two direct reports focused on payer evidence requirements needed to maximize commercial potential of products in development● Selected to speak at Pharma Pricing and Market Access Outlook Europe on the topic of “Risk-Based Pricing: Current Practice and Future Outlook in Healthcare”

Responsible for translating payer needs to evidence requirements for Disease Area Strategy, Phase II, and Phase III study designs. Lead all pricing assessments and deliver pricing strategies for priority disease areas and products in development. • Led the Global Payer Initiative for the Neuroscience R&D organization and established specific payer objectives in the 2011 corporate scorecard including delivery of two Disease Area Global Reimbursement Dossiers• Led payer gap analysis and mitigation plan for four priority disease areas and secured investment to deliver tactical plan• Delivered payer evidence requirements for three Phase II study investment decisions of key asset and secured inclusion of payer-centric endpoints in study design• Developed pricing and reimbursement strategy for two Phase III study investment decisions and secured inclusion of data collection requirements to meet payer demands• Partnered with Health Economics and Outcomes Research to develop Cost-Effectiveness and Budget Impact models for major launch brand

Led teams of commercial, medical, and health economics professionals to create Global Pricing and Reimbursement strategies for key compounds in Phases II and III of development. Responsible for maintaining Global Price and Reimbursement positions of marketed products by partnering with Product Management and local country personnel.• Led price and reimbursement due-diligence team in support of $400 million global business development deal signed December 2005. • Influenced Phase III trial design of key asset by convincing R&D team to include endpoints required by payers for reimbursement consideration.

Accountable for all personal and non-personal promotion for Fosrenol launched January 2005 to treat patients with End Stage Renal Disease. Led all activities of Advertising and Public Relations agencies.• Developed all promotional materials and marketing message platform to support the launch of Fosrenol. Met sales projections of investment community 3 months post launch.• Facilitated regional Advisory Boards of Key Opinion Leaders and physicians • Managed a $17 million Advertising and Promotional budget.

Responsible for US pricing and reimbursement strategy for key brands exceeding $4B in US revenue. Provided strategy consultation to customer teams responsible for largest managed markets accounts. • Designed economic model to illustrate Avandamet’s cost advantage to support market penetration strategy. Designed and led a comprehensive training module to prepare over 100 key account managers to use the economic model with customers. Avandamet reached its goal of 90% formulary coverage six months post-launch. • Developed the US price and reimbursement strategy for Levitra. Managed the internal negotiations across Bayer and GSK to secure the final price and reimbursement strategy

Developed revenue forecasts for early stage, in-license compound opportunities to influence Lilly’s investment decision, with an emphasis in the Diabetes and Oncology therapeutic areas. Conducted primary market research with physicians and secondary, internet-based research to establish key assumptions that drive the forecasts.Led the managed markets marketing efforts of Lilly's diabetes portfolio specifically product pricing and positioning. Led the business planning process for a department of 280 employees. Developed an e-commerce strategy for Lilly's managed markets organization.

Developed marketing strategy for a new product scheduled for launch in 2002. Made specific recommendations for an aggressive educational campaign, a specialized 20-person sales force, and a unique distribution network.

Successfully completed GE's Technical Leadership Program in 1996. Developed cross-functional team leadership through assignments in sales, marketing, and engineering. First program member to be selected for an international field sales assignment.